Three healthily skeptical primary care physicians discuss the latest in primary care medicine. Join Essential Evidence Editor Mark Ebell MD, JFP editor John Hickner MD, and POEMs co-founder Henry Barry MD, for this fast-paced weekly update on evidence-based primary care.
The best episodes ranked using user listens.
Episode 31: T2DM treatment, T2DM with CVD or CKD, and pre-diabetes
A whole lotta diabetes goin' on: linagliptin ($780) vs glimepiride ($3) for T2DM (https://www.ncbi.nlm.nih.gov/pubmed/31536101); semaglutide in T2DM + vascular/CKD (https://www.ncbi.nlm.nih.gov/pubmed/31185157); and whether we should care about pre-diabetes (https://www.ncbi.nlm.nih.gov/pubmed/31076416).
14 Nov 2019